{"id":2459,"date":"2026-08-30T08:59:30","date_gmt":"2026-08-30T08:59:30","guid":{"rendered":"https:\/\/one-peptides.com\/?p=2459"},"modified":"2026-09-30T11:56:01","modified_gmt":"2026-09-30T11:56:01","slug":"mk-677-vs-ghrp-2-and-ghrp-6-what-the-research-says","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/de\/mk-677-vs-ghrp-2-and-ghrp-6-what-the-research-says\/","title":{"rendered":"MK-677 vs GHRP-2 and GHRP-6 \u2014 What Does the Research Say?"},"content":{"rendered":"

In brief.<\/strong> MK-677 and GHRP peptides activate the same receptor<\/strong> \u2014 GHS-R1a, the ghrelin receptor \u2014 but they belong to different molecular classes. MK-677 (ibutamoren)<\/strong> is a non-peptide compound active after oral administration<\/strong>; a 12-month study in healthy older adults reported increased lean body mass and enhanced pulsatile growth hormone secretion (Nass et al., 2008). GHRP-2 and GHRP-6<\/strong> are peptides<\/strong> administered parenterally in research and have a short duration of action. The distinction concerns molecular structure, route of administration and exposure profile, not a simple ranking of potency. Both classes are included in category S2 of the WADA Prohibited List, and none is approved as a medicine; catalogue products are Research Use Only reagents.<\/em><\/p>\n

This educational article reviews published research on growth hormone secretagogues. Reported effects are limited to the clinical, animal and receptor models described in the cited literature and are not claims about outcomes in readers. This text is not medical advice. One Peptides catalogue compounds are intended solely for laboratory research (Research Use Only).<\/p>\n

How does MK-677 differ from GHRP-2 and GHRP-6?<\/h2>\n

The shared mechanism is important: all three compounds activate the same receptor<\/strong>. GHS-R1a, the growth hormone secretagogue receptor, is the physiological receptor for ghrelin, a hormone released mainly by the stomach. Structural work on the receptor showed that ghrelin and ibutamoren occupy the same binding pocket despite their very different chemical structures (Liu et al., 2021).<\/p>\n

The difference lies in what the molecules are<\/strong>. GHRP-2 and GHRP-6 are short peptides that are degraded in the gastrointestinal tract and are administered parenterally in research. MK-677 is a non-peptide compound designed to survive gastrointestinal passage and remain active after oral administration. This property shapes its duration of action, experimental design and the types of studies that could be conducted.<\/p>\n

Table: MK-677 vs GHRP-2 and GHRP-6<\/h3>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nMK-677 (ibutamoren)<\/th>\nGHRP-2 and GHRP-6<\/th>\n<\/tr>\n
Chemical class<\/th>\nNon-peptide compound (ghrelin mimetic)<\/td>\nPeptides (hexapeptides)<\/td>\n<\/tr>\n
Target receptor<\/th>\nGHS-R1a (ghrelin receptor)<\/td>\nGHS-R1a \u2014 the same receptor<\/td>\n<\/tr>\n
Route used in studies<\/th>\nOral<\/td>\nParenteral<\/td>\n<\/tr>\n
Duration of action<\/th>\nLong, daily profile<\/td>\nShort, pulsatile profile<\/td>\n<\/tr>\n
Longest human study<\/th>\n12 months<\/td>\nShort diagnostic protocols<\/td>\n<\/tr>\n
Historical role<\/th>\nSecond-generation oral mimetic<\/td>\nGHRP-6 was an early research tool for this axis; GHRP-2 was developed later<\/td>\n<\/tr>\n
Signal selectivity<\/th>\nDescribed as similar to GHRPs<\/td>\nGHRP-6 more clearly stimulates appetite and may co-release cortisol and prolactin<\/td>\n<\/tr>\n
WADA status<\/th>\nProhibited \u2014 category S2<\/td>\nProhibited \u2014 category S2<\/td>\n<\/tr>\n
Approved as a medicine<\/th>\nNo<\/td>\nNo<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

How does MK-677 (ibutamoren) work?<\/h2>\n

MK-677 is a non-peptide GHS-R1a agonist<\/strong> described as a ghrelin mimetic. Receptor activation in the pituitary and hypothalamus increases the release of endogenous growth hormone. The compound is neither growth hormone nor a growth hormone analogue; it is a stimulus to the somatotropic axis.<\/p>\n

Early studies reported that daily oral MK-677 stimulated the growth hormone\u2013IGF-I axis in healthy older adults (Chapman et al., 1996). Longer protocols found that the effect persisted and also reported changes in sleep architecture (Copinschi et al., 1997).<\/p>\n

The strongest reference point is a 12-month randomized trial published in Annals of Internal Medicine<\/em>. In healthy adults aged 60\u201381 years, one year of oral MK-677 enhanced pulsatile growth hormone secretion and significantly increased lean body mass versus placebo. The authors reported that it was generally well tolerated in the study population, while noting that the sample was too small to assess functional outcomes (Nass et al., 2008). This unusually long study is the principal reason MK-677 has the broadest human evidence base in this class.<\/p>\n

A separate article provides a broader review of MK-677 research<\/a>, while available reagents are grouped in the MK-677 category<\/a>.<\/p>\n

How do GHRP-2 and GHRP-6 work?<\/h2>\n

GHRP-6 is a hexapeptide first described in the 1980s and was historically one of the earliest widely studied compounds in this family (Bowers et al., 1984). It predates the discovery of ghrelin and helped researchers characterize the receptor and its role in growth hormone release. GHRP-2, also known as pralmorelin, was developed later and optimized more specifically for growth hormone secretion.<\/p>\n

The two peptides differ in signal selectivity<\/strong>. GHRP-6 clearly stimulates appetite, consistent with GHS-R1a being the physiological receptor for the hunger hormone ghrelin (M\u00fcller et al., 2015), and it is associated with more pronounced co-release of cortisol and prolactin. GHRP-2 is generally described as producing a cleaner isolated growth hormone response (Camanni et al., 1998; Ghigo et al., 1997).<\/p>\n

GHRP-2 has also been used diagnostically. A stimulation test was developed and validated for diagnosing adult growth hormone deficiency (Chihara et al., 2007). This contrasts with MK-677: most GHRP human data come from short provocation or diagnostic protocols, not year-long body-composition trials.<\/p>\n

The guide to GHRP-2 and GHRP-6 secretagogues<\/a> reviews this family in detail, while a separate article offers a direct comparison of GHRP-2 and GHRP-6<\/a>. Reagents are grouped in the GHRP-2<\/a> and GHRP-6<\/a> categories.<\/p>\n

Why are they not interchangeable?<\/h2>\n

A shared receptor may suggest interchangeability, but the literature does not support that conclusion for three reasons.<\/p>\n

First, their time profiles differ<\/strong>. GHRP peptides produce a short, acute stimulus, whereas MK-677 has a daily exposure profile. These are different patterns of axis activation, not the same intervention delivered by another route.<\/p>\n

Second, the scope of evidence differs<\/strong>. MK-677 has a 12-month randomized trial with body composition as an outcome. GHRP-2 and GHRP-6 are represented mainly by short provocation protocols and diagnostic work. Findings cannot be transferred from one class to the other because the time horizons and endpoints differ.<\/p>\n

Third, their routes of administration differ<\/strong>. Oral activity is a defining property of MK-677, not a minor technical detail. GHRP peptides do not share this property and were administered parenterally in research.<\/p>\n

The peptide family also includes ipamorelin<\/a>, described as the first selective growth hormone secretagogue because it released growth hormone without a significant accompanying rise in cortisol or prolactin (Raun et al., 1998).<\/p>\n

What is known about the safety of these compounds?<\/h2>\n

The evidence differs primarily in observation length rather than in the type of signal reported.<\/p>\n

For MK-677, the 12-month randomized trial described the compound as generally well tolerated in the study population, while explicitly noting the small sample and inability to assess functional outcomes (Nass et al., 2008). Research on this class also reports changes in glucose-metabolism parameters when the growth hormone axis is stimulated, a variable that requires monitoring in each experimental model (Nass et al., 2011).<\/p>\n

For GHRP-2 and GHRP-6, the data come from short protocols. Their profile during chronic exposure therefore remains undescribed; controlled short-term administration cannot establish a long-term safety profile.<\/p>\n

Both classes share important uncertainties: no multi-year exposure data, no completed registration studies and no established safety profile outside the conditions of the published experiments. None completed a medicinal-product approval pathway.<\/p>\n

What is the anti-doping status of MK-677 and GHRPs?<\/h2>\n

All three compounds are included in category S2<\/strong> of the WADA Prohibited List, which covers peptide hormones, growth factors, related substances and mimetics. The category explicitly includes growth hormone secretagogues and ghrelin receptor agonists and applies both in and out of competition.<\/p>\n

MK-677 being non-peptide does not alter its status because category S2 includes mimetics regardless of chemical structure. Anti-doping laboratories also have validated analytical methods for this class, including liquid chromatography\u2013tandem mass spectrometry detection of pralmorelin (GHRP-2) and its metabolite in urine (Okano et al., 2010).<\/p>\n

Frequently Asked Questions<\/h2>\n

Is MK-677 a peptide?<\/strong> No. MK-677 (ibutamoren) is a non-peptide, orally active ghrelin mimetic. It activates the same GHS-R1a receptor as GHRP peptides but has a different chemical structure that allows oral administration in research.<\/p>\n

Do MK-677 and GHRPs activate the same receptor?<\/strong> Yes. MK-677, GHRP-2 and GHRP-6 are agonists of GHS-R1a, the ghrelin receptor.<\/p>\n

How does MK-677 differ from GHRP-2 and GHRP-6?<\/strong> They differ in molecular structure, route of administration and exposure profile. MK-677 is a non-peptide compound used orally in studies and has a daily profile. GHRP-2 and GHRP-6 are short-acting peptides administered parenterally in research.<\/p>\n

Can these compounds be treated as interchangeable?<\/strong> No. A shared receptor does not make their evidence transferable. Their time profiles, routes of administration and study horizons differ, so conclusions from one molecular class cannot automatically be applied to the other.<\/p>\n

Which compound has the broader human evidence base?<\/strong> MK-677 has the broader long-term human dataset, including a 12-month randomized trial in healthy older adults that assessed body composition (Nass et al., 2008). GHRP-2 also has human diagnostic data, but from short protocols.<\/p>\n

Are MK-677 and GHRPs prohibited in sport?<\/strong> Yes. Category S2 of the WADA Prohibited List covers growth hormone secretagogues and ghrelin receptor agonists. Their different molecular structures do not change this status.<\/p>\n

Is any of these compounds an approved medicine?<\/strong> No. MK-677, GHRP-2 and GHRP-6 are not approved as medicinal products and are marketed here solely as laboratory research reagents<\/a>.<\/p>\n

Conclusion \u2014 the same receptor, two different molecular classes<\/h2>\n

MK-677, GHRP-2 and GHRP-6 converge at GHS-R1a but differ in nearly every other respect. MK-677 is an orally active non-peptide mimetic with the longest human study in the class (12 months). GHRP-2 and GHRP-6 are parenterally administered peptides and historically important research tools supported mainly by short protocols. Both molecular classes fall under category S2 of the WADA Prohibited List and remain unapproved research reagents.<\/p>\n

For experimental design, the practical distinction is straightforward: the same molecular target, but a different pattern of axis activation and a non-comparable evidence base.<\/p>\n

RUO disclaimer.<\/strong> MK-677 (ibutamoren)<\/a>, GHRP-2 and GHRP-6 in the One Peptides catalogue are chemical reagents intended solely for laboratory and scientific research (Research Use Only). They are not medicines, dietary supplements or products intended for consumption or administration to humans or animals outside a controlled experimental setting. All effects described are findings reported in the cited models, not claims of efficacy or indications for use. This information is educational and scientific and is not medical or pharmaceutical advice. All compounds discussed are included in category S2 of the WADA Prohibited List.<\/em><\/p>\n

References<\/h2>\n
    \n
  1. Nass R, Pezzoli SS, Oliveri MC et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial<\/cite><\/a><\/li>\n
  2. Chapman IM, Bach MA, Van Cauter E et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects<\/cite><\/a><\/li>\n
  3. Copinschi G, Leproult R, Van Onderbergen A et al. (1997). Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man<\/cite><\/a><\/li>\n
  4. Liu H, Sun D, Myasnikov A et al. (2021). Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren<\/cite><\/a><\/li>\n
  5. Bowers CY, Momany FA, Reynolds GA, Hong A (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone<\/cite><\/a><\/li>\n
  6. Ghigo E, Arvat E, Muccioli G, Camanni F (1997). Growth hormone-releasing peptides<\/cite><\/a><\/li>\n
  7. Camanni F, Ghigo E, Arvat E (1998). Growth hormone-releasing peptides and their analogs<\/cite><\/a><\/li>\n
  8. M\u00fcller TD, Nogueiras R, Andermann ML et al. (2015). Ghrelin<\/cite><\/a><\/li>\n
  9. Chihara K, Shimatsu A, Hizuka N et al. (2007). A simple diagnostic test using GH-releasing peptide-2 (GHRP-2) in the diagnosis of adult GH deficiency<\/cite><\/a><\/li>\n
  10. Okano M, Sato M, Kageyama S et al. (2010). Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography\/electrospray ionization tandem mass spectrometry<\/cite><\/a><\/li>\n
  11. Raun K, Hansen BS, Johansen NL et al. (1998). Ipamorelin, the first selective growth hormone secretagogue<\/cite><\/a><\/li>\n
  12. Nass R, Gaylinn BD, Thorner MO (2011). The role of ghrelin in GH secretion and GH disorders<\/cite><\/a><\/li>\n<\/ol>\n

    Regulatory source: World Anti-Doping Agency, Prohibited List, category S2 (peptide hormones, growth factors, related substances and mimetics), including growth hormone secretagogues and ghrelin receptor agonists: WADA Prohibited List<\/a>.<\/em><\/p>\n